Great Find Nick8
I dont think the readers have actually read or anaylsed this CSIRO information on ADAPT.
The CSIRO report was from Feb 2015 over 11 months ago. Nothing posted ever since yet the CSIRO research was commissioned in Feb 2014 so they had 12 months of work on ADAPT CC yet thats all they released publicly.
Its a secret KGB lab in Siberia still.
Lets analyse what CSIRO actually says on their site:-
"THE RESULTS
A new pulse for heart health
- This research identified a new set of potential business opportunities for Admedus’ existing product CardioCel.
- Chief Scientific Officer, David Rhodes, said, “Through combining [our] expertise with that of CSIRO, we see the potential for additional projects with CSIRO down the track. There are other techniques we would like to explore."
- “The results have shown that CardioCel enhances the ability for tissues to repair and that it is well-suited for cardiovascular cell therapy,” said CSIRO’s Dr Werkmeister.
- The results showed that the company’s novel engineering process used to prepare CardioCel provides a superior tissue platform for growing stem cells.
- “There is the potential to use our material in other areas of stem cell delivery as well, for example it might help speed the recovery when used in the repair of knee joints or in the rebuilding of vessels,” said Dr Rhodes. “While this still needs further research, these results are promising and we have the grounds for exploring it further.”
So this is my analysis:-
- 12 months no news, kept secret no updates
- the report IS OLD AND OUTDATED 11 months ago, very platonic and not revealing much at all
- no mention of cranial, hernia or vascular or carotid applications
- the reference to vessels does not define "vascular" or what any type so presume its a broad coverage of veins, arteries, blood vessels even other biological vessels such as respiratory or reproductive tubes
- the reference to knee joints (patella/ligament repair) is stunning as no mention of this from AHZ, CC used for ligaments would be a massive breakthrough and expand applications 20 fold into areas such as hip surgery, sport injuries, elderly surgeries
- multiple mention of stem cell (the new buzzword)
- stem cell delivery clearly features largely for CSIRO and may well relate to carotid or cranial, muscle & ligament repair
- stem cells are not needed for vessel repair or heart patch repair
- additional project down the track yet nothing for 11 months and no news of which projects and what body parts, very vague and secretive
- "other projects" to trial...yet no details of which and what body parts
- CSIRO is clearly excited and heavily promoting/trialing CC/ADAP
- CSIRO has a clear mandate for expanded studies and works in undefined areas beyond stem cells even, seems beyond a commercial study involved here
- the stem cell delivery area is bodywide and can be used for multiple organs and systems
- CSIROs work has clearly defined areas not thought of before and AHZs timeline clearly indicates they must have been doing studies and work on carotid, vascular, knee joint/ligament, vessel & stem cell platforms
Where is the value in AHZ SP for this 100 fold expansion of CC ADAPT products over the coming years? Non existent!
(20min delay)